The Hematology Research Training Program at the University of Pennsylvania was established in 1978 and is currently in its 19th year of funding, the last four of which have been under the current principal investigator, Lawrence Brass. Throughout that time, the goal has been to help top candidates with an interest in the broadly-defined disciplines of hematology and, more recently, vascular biology to prepare themselves for academic careers in which their scientific training in laboratories could be applied to either laboratory or clinical research. During the first 19 years of funding, 70 postdoctoral trainees and one pre-doctoral trainee have been supported for work in 33 different laboratories: 57 M.D., 9 M.D.-Ph.D. and 4 Ph.D. Twenty of the trainees were women, 51 were men. Of the 64 trainees who have completed training to date, 41 (64%) hold full-time appointments at an academic institution and are engaged in either laboratory (22%) or clinical (42%) research. An additional 7 (11%) are engaged primarily in clinical practice, but have university appointments and participate in clinical research projects and teaching part-time. The remaining 25% are either not working for a variety of reasons (5%), employed in industry (3%) or engaged in full time private practice (17%). Approximately half of our former trainees have extramural research funding with direct costs in the current year exceeding $7 million. Graduates of this program hold appointments at 21 institutions around the United States, including the University of Pennsylvania, Harvard and the NIH. Among the program graduates there are currently 3 full professors, 11 associated professors, 20 assistant professors and 4 instructors. This proposal provides follow-up information on all of the trainees since the inception of the grant and describes how the program has evolved during the past two decades. Based on the success of the training program to date, the availability of additional strong candidates, and the growth of the faculty and programs in hematology and vascular biology, this proposal also makes the case for an increase in funding from the current 5 M.D., M.D.-Ph.D. and Ph.D. postdoctoral positions per year to 8 per year.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
2T32HL007439-21
Application #
2800316
Study Section
Special Emphasis Panel (ZHL1-CSR-K (F1))
Project Start
1979-07-01
Project End
2004-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
21
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brenner, Jacob S; Kiseleva, Raisa Yu; Glassman, Patrick M et al. (2018) The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). Pulm Circ 8:2045893217752329
Bagashev, Asen; Sotillo, Elena; Tang, Chih-Hang Anthony et al. (2018) CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol Cell Biol :
Greineder, Colin F; Villa, Carlos H; Walsh, Landis R et al. (2018) Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting. Bioconjug Chem 29:56-66
Kiseleva, Raisa Yu; Glassman, Patrick M; Greineder, Colin F et al. (2018) Targeting therapeutics to endothelium: are we there yet? Drug Deliv Transl Res 8:883-902
Greineder, Colin F; Johnston, Ian H; Villa, Carlos H et al. (2017) ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model. Blood Adv 1:1452-1465
Thalji, Nabil K; Camire, Rodney M (2017) Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol 24:453-459
George, Lindsey A; Sullivan, Spencer K; Giermasz, Adam et al. (2017) Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med 377:2215-2227
Zhen, Tao; Kwon, Erika M; Zhao, Ling et al. (2017) Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11. Blood 130:2431-2442
Peslak, Scott A; Olson, Timothy; Babushok, Daria V (2017) Diagnosis and Treatment of Aplastic Anemia. Curr Treat Options Oncol 18:70
Carnemolla, Ronald; Villa, Carlos H; Greineder, Colin F et al. (2017) Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. FASEB J 31:761-770

Showing the most recent 10 out of 118 publications